Lastly, enhancement in immune response was assessed in both prophylactic and therapeutic vaccine studies involving B16‐OVA melanoma, in which the CpG‐OVA‐HAC2 slowed tumor growth and enhanced survival relative to unvaccinated mice and mice receiving bolus vaccination. Here, HCN1 is linked to melanoma.